NCT06345404 - Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Participants With Moderate to Severe AD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 23, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

November 30, 2025

Conditions

Atopic Dermatitis

Interventions

DRUG

Soquelitinib

Tablets

DRUG

Placebo

Soquelitinib matching placebo tablets

Trial Locations (16)

10023

RECRUITING

Clinical Site 16, New York

10075

RECRUITING

Clinical Site 12, New York

11203

RECRUITING

Clinical Site 11, Brooklyn

17011

RECRUITING

Clinical Site 1, Camp Hill

19103

RECRUITING

Clinical Site 8, Philadelphia

33615

RECRUITING

Clinical Site 6, Tampa

35244

RECRUITING

Clinical Site 5, Birmingham

44124

RECRUITING

Clinical Site 15, Mayfield Heights

72117

RECRUITING

Clinical Site 3, North Little Rock

75034

RECRUITING

Clinical Site 4, Frisco

78213

RECRUITING

Clinical Site 14, San Antonio

80109

RECRUITING

Clinical Site 10, Castle Rock

85704

RECRUITING

Clinical Site 9, Tucson

91767

RECRUITING

Clinical Site 13, Pomona

94063

RECRUITING

Clinical Site 7, Palo Alto

94538

RECRUITING

Clinical Site 2, Fremont